A prospective study on the efficacy of dupilumab in chronic rhinosinusitis with type 2 inflammation

Objective. Treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) includes en-doscopic sinus surgery and topic and/or systemic corticosteroids, which have only tempo-rary effects. The development of biologic therapies has provided a new treatment paradigm for CRSwNP. Dupilumab is the only biological approved in Italy for CRSwNP, but its efficacy in a real-life context is still scarce. Methods. We carried out a monocentric prospective study at our institution with a 6-month follow-up on patients administered biweekly 300 mg dupilumab therapy for CRSwNP, pre-scribed according to EPOS 2020 criteria. Patients were evaluated at baseline and every 2 months.Results. Median values at baseline and 6 months were, respectively, 3/12 and 8/12 for the Brief Smell Identification Test (p = 0.005), 5/8 and 2/8 for the Nasal Polyp Score (p < 0.001), 10/20 and 6/20 for the Lund-Kennedy score (p < 0.001), 65/110 and 14/110 for the Sinonasal Outcome Test (p < 0.001), and 15/25 and 23/25 for the Asthma Control Test score (p = 0.009). Adverse events were mild, consisting mainly in discomfort at the site of injection. Four patients developed asymptomatic hypereosinophilia. The treatment was not discontinued in any patient.Conclusions. Dupilumab was confirmed to be an effective and safe treatment for CRSwNP, as previously seen in registrational studies.